CL2017001680A1 - Composición farmacéutica para el tratamiento de enfermedades gastrointestinales - Google Patents

Composición farmacéutica para el tratamiento de enfermedades gastrointestinales

Info

Publication number: CL2017001680A1
Authority: CL; Chile
Prior art keywords: treatment; pharmaceutical composition; gastrointestinal diseases; sucralphate; subcitrate
Prior art date: 2015-01-30

Application number

CL2017001680A

Other languages

English (en)

Spanish (es)

Inventor

Jun Woo Lee

Young Ho Jo

Original Assignee

Dae Woong Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-30

Filing date

2017-06-23

Publication date

2018-01-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-06-23 Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma

2018-01-12 Publication of CL2017001680A1 publication Critical patent/CL2017001680A1/es

Links

208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 3
229960000620 ranitidine Drugs 0.000 abstract 3
229940000425 combination drug Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2017001680A 2015-01-30 2017-06-23 Composición farmacéutica para el tratamiento de enfermedades gastrointestinales CL2017001680A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20150015339		2015-01-30
KR1020150147513A KR101583452B1 (ko)	2015-01-30	2015-10-22	위장질환 치료용 의약 조성물

Publications (1)

Publication Number	Publication Date
CL2017001680A1 true CL2017001680A1 (es)	2018-01-12

Family

ID=55169799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2017001680A CL2017001680A1 (es)	2015-01-30	2017-06-23	Composición farmacéutica para el tratamiento de enfermedades gastrointestinales

Country Status (19)

Country	Link
EP (1)	EP3250199A4 (fr)
JP (1)	JP6419347B2 (fr)
KR (2)	KR101583452B1 (fr)
CN (1)	CN107205947B (fr)
AR (1)	AR105413A1 (fr)
CL (1)	CL2017001680A1 (fr)
CO (1)	CO2017006222A2 (fr)
EA (1)	EA032385B9 (fr)
EC (1)	ECSP17038599A (fr)
GE (2)	GEP20196941B (fr)
MA (1)	MA41432A (fr)
MX (1)	MX375765B (fr)
MY (1)	MY195824A (fr)
PE (1)	PE20171340A1 (fr)
PH (1)	PH12017550051A1 (fr)
SA (1)	SA517382016B1 (fr)
TW (1)	TWI635859B (fr)
UA (1)	UA116517C2 (fr)
WO (1)	WO2016122226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101988479B1 (ko)	2017-10-11	2019-09-24	(주)휴럼	리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (fr) *	2018-04-13	2019-10-17	주식회사 삼양바이오팜	Composition pharmaceutique comprenant du lénalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3874917T2 (de) *	1987-03-09	1993-03-04	Procter & Gamble	Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) *	1988-08-25	1991-02-05	Applied Analytical Industries, Inc.	Method for preparing high potency sucralfate
EP0403048A3 (fr) *	1989-06-14	1991-01-30	Warner-Lambert Company	Un modèle de structure de système craniomandibulaire humain
KR970006083B1 (ko) *	1992-01-22	1997-04-23	주식회사 대웅제약	위장질환 치료용 의약 조성물
ATE213635T1 (de) *	1994-04-26	2002-03-15	Chugai Pharmaceutical Co Ltd	Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
JPH0879097A (ja) *	1994-09-01	1996-03-22	Matsushita Electric Ind Co Ltd	携帯無線機
KR970006083A (ko)	1995-07-06	1997-02-19	한승준	자동차용 카울부의 와이어 고정장치 취부구조
JP2001513570A (ja) *	1997-08-25	2001-09-04	ザ、プロクター、エンド、ギャンブル、カンパニー	上部胃腸管不調治療用複合製剤
WO2000078307A1 (fr) *	1999-06-21	2000-12-28	Daewoong Pharmaceutical Co., Ltd.	Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
JP2006076956A (ja) *	2004-09-10	2006-03-23	Taiyo Yakuhin Kogyo Kk	胃炎の治療・予防用配合剤
KR101617054B1 (ko) *	2008-07-01	2016-04-29	라이온 가부시키가이샤	고형내복제제
KR20110105223A (ko) *	2010-03-18	2011-09-26	일양약품주식회사	일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) *	2012-12-05	2014-06-13	(주)한국파비스제약	경구용 위장질환 치료를 위한 정제

2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/ko active Active
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/ko not_active Withdrawn
2016
- 2016-01-27 MA MA041432A patent/MA41432A/fr unknown
- 2016-01-27 TW TW105102582A patent/TWI635859B/zh active
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-28 EA EA201791458A patent/EA032385B9/ru not_active IP Right Cessation
- 2016-01-28 MX MX2017007567A patent/MX375765B/es active IP Right Grant
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/zh active Active
- 2016-01-28 GE GEAP201814551A patent/GEP20186941B/en unknown
- 2016-01-28 UA UAA201707833A patent/UA116517C2/uk unknown
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/es unknown
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/fr not_active Ceased
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/ja active Active
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/fr not_active Withdrawn
- 2016-01-29 AR ARP160100272A patent/AR105413A1/es not_active Application Discontinuation
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/es unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/es unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/es unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/ar unknown

Also Published As

Publication number	Publication date
JP6419347B2 (ja)	2018-11-07
WO2016122226A2 (fr)	2016-08-04
EP3250199A4 (fr)	2018-08-08
MX2017007567A (es)	2017-10-19
KR20160094268A (ko)	2016-08-09
KR101583452B1 (ko)	2016-01-11
PE20171340A1 (es)	2017-09-13
ECSP17038599A (es)	2017-09-29
PH12017550051A1 (en)	2018-01-29
CN107205947B (zh)	2020-05-22
GEAP201814551A (en)	2018-08-27
KR101583452B9 (ko)	2022-05-02
TW201639559A (zh)	2016-11-16
MA41432A (fr)	2017-12-05
EA201791458A1 (ru)	2017-11-30
GEP20186941B (en)	2019-01-10
WO2016122226A3 (fr)	2016-09-15
SA517382016B1 (ar)	2021-03-18
EA032385B1 (ru)	2019-05-31
CN107205947A (zh)	2017-09-26
JP2018503672A (ja)	2018-02-08
BR112017013857A2 (pt)	2018-02-27
AR105413A1 (es)	2017-10-04
CO2017006222A2 (es)	2017-09-20
TWI635859B (zh)	2018-09-21
MX375765B (es)	2025-03-07
UA116517C2 (uk)	2018-03-26
EA032385B9 (ru)	2019-07-31
EP3250199A2 (fr)	2017-12-06
GEP20196941B (en)	2019-01-10
MY195824A (en)	2023-02-22

Publication	Publication Date	Title
CL2020000501A1 (es)	2020-07-10	Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2018000684A1 (es)	2018-12-28	Moduladores de la proteína de núcleo de la hepatitis b.
MX2021008113A (es)	2021-10-13	Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2020004467A (es)	2020-10-22	Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2018000223A1 (es)	2018-07-13	Combinación de antagonista de pd-1 con un inhibidor de egfr
DOP2016000233A (es)	2016-12-30	MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
CL2018000706A1 (es)	2018-07-13	Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MX2017002028A (es)	2017-08-14	Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CR20170361A (es)	2018-01-25	Forma de dosificación que incluye una solución sólida de drogas amorfas
EA201691988A1 (ru)	2017-06-30	Производные бороновой кислоты и их терапевтическое применение
MX2015010312A (es)	2015-11-18	Metodos para tratamiento del melanoma.
ECSP17053843A (es)	2017-11-30	Formulación nasal en polvo para el tratamiento de hipoglicemia
CL2017001483A1 (es)	2018-02-23	Formulación de relación fija de insulina glargina/lixisenatida
ECSP16084317A (es)	2018-05-31	Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2018012618A (es)	2019-06-24	Composiciones farmaceuticas orales de mesalazina.
MX2017004772A (es)	2017-10-12	Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX2017012596A (es)	2018-01-09	Una composicion farmaceutica y el uso de la misma.
BR112016028316A2 (pt)	2017-08-22	composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
CL2016002879A1 (es)	2017-02-24	Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2016015261A (es)	2017-08-15	Dispersion solida de allisartan isoproxilo y su composicion.
MX2017010341A (es)	2018-06-06	Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2016014740A (es)	2017-03-06	Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX368268B (es)	2019-09-26	Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
BR112016028083A2 (pt)	2017-08-22	Composição oral farmacêutica de isotretinoina e seu processo de preparação
MX2016005227A (es)	2016-08-12	Polipéptidos de acción prolongada y métodos para su producción y administración.